imphatec raises £1.5m seed led by SynBioVen
This article covers imphatec, a British synthetic biology pharmaceutical startup, which has closed an oversubscribed £1.5m seed funding round led by SynBioVen with participation from angel investors. The funding will support further development of its subcutaneous implant drug-delivery platform, which aims to replace daily pills for people with chronic and long-term conditions and to advance the lead programmes toward human clinical trials.
imphatec, a British synthetic biology pharmaceutical company, has closed an oversubscribed £1.5m seed funding round led by SynBioVen, with participation from angel investors. The money will fund further development of imphatec’s subcutaneous implant platform, a drug-delivery technology the company says could replace daily pills for people with chronic and long-term conditions and move its lead programmes toward human clinical trials.
Why it matters
Millions of patients with chronic conditions rely on daily medication, and non-adherence is a persistent clinical and economic problem. The World Health Organization estimates that about half of these patients do not take medicines as prescribed, increasing the risk of complications and healthcare costs. Conventional oral dosing also means a variable fraction of each dose reaches target tissues.
A device that provides automatic, long-term, uniform dosing could improve adherence and pharmacokinetics for conditions that currently require daily medication, such as hypothyroidism. If the platform proves safe and effective in humans, it could change how common chronic therapies are delivered and reduce the daily treatment burden on patients and health systems.
Inside the product
imphatec is developing a subcutaneous implant platform that releases medication over extended periods with no ongoing patient input. The implants are designed to deliver personalised dose profiles tailored to individual needs, and the company positions the technology as a platform that can be applied to a range of established medications rather than a single therapeutic product.
According to the announcement, the implants have already passed pre-clinical experimental stages. The new funding is earmarked to support the next development milestones as imphatec advances its experimental pipeline toward full human clinical trials.
Who are the investors?
The round was led by SynBioVen and described as oversubscribed, with angel investors also taking part. SynBioVen is positioned in the announcement as providing scientific expertise to guide imphatec through the upcoming development stages.
In the announcement, Richard Kitney, SynBioVen, said:
The successful completion of imphatec’s seed round is an important step in the company’s development. The implant technology that they are developing has important implications for the daily treatment of hypothyroidism – removing the need for patients to take daily medication for the condition. imphatec’s implant technology has the ability to provide patients with automatic uniform dosage. The new investment will allow the company to proceed with the development of its technology towards full human clinical trials. It is anticipated in the future the core technology can be modified for a wider range of clinical conditions to remove the need for treatment requiring treatment daily pill usage.
If you're researching potential backers in this space:
- Explore our list of healthtech venture capital firms in the UK
- Browse our directory of healthtech angel investors in the UK
Founder perspective
In the announcement, Hassan O. J. Morad, Co-founder & CSO at imphatec, said:
The investment in this round, led by SynBioVen, will drive the next key development stages of our implant platform to treat chronic and long-term conditions. Our implants have previously progressed with success through pre-clinical experimental stages, and this investment will allow us to advance further along the experimental pipeline towards the clinic. SynBioVen brings a wealth of scientific expertise that will allow us to navigate through the upcoming stages of development as we look to modernise and improve options for patients suffering with chronic and long-term conditions.
The bigger picture
imphatec’s raise is another example of early-stage capital flowing into platform healthtech and synthetic biology projects that aim to rework how medicines are delivered rather than invent entirely new drugs. The technical and regulatory path from pre-clinical success to routine clinical use is long: human safety, long-term biocompatibility, manufacturing, and regulatory approval for combination product-device constructs will all be critical hurdles.
The involvement of a specialist investor like SynBioVen and a syndicate of angels signals continued interest from healthtech investors in platform technologies that could unlock new commercial pathways for existing therapeutics. For the UK and Europe, where medtech and synthetic biology clusters are expanding, these kinds of seed rounds help bridge academic research and clinical translation.
This funding round underlines a broader trend in the UK and European biotech ecosystem: investors are increasingly backing platform approaches that aim to improve patient adherence and outcomes while leveraging established drugs. imphatec’s progress to human trials will be one to watch for signals about the feasibility and scalability of long-term implant-based drug delivery.
They've invested in imphatec
Get to know these healthtech investors
| Investors | Investment Focus | Startup Investments | Round Size | Connect |
|---|---|---|---|---|
 | ||||
| All investors | All investor sectors | All funded startups | All funding rounds |
Click here for a full list of 7,589+ startup investors in the UK